Prevalence, evolution, and features of infection with human papillomavirus: A 15-year longitudinal study of routine screening of a women population in the north of Spain

Journal of Medical Virology

Volumn 82, Issue 4, 2010, Pages 597-604

  De Oña, María ^a   Alvarez Argüelles, Marta E ^a   Torrents, Magdalena ^a   Villa, Laura ^a   Rodriguez Feijoo, Asunción ^b   Palacio, Ana ^a   Boga, Jose A ^a   Tamargo, Angel ^a   Melón, Santiago ^a  

^a Hospital de Asturias   (Spain)

^b HOSPITAL XERAL CALDE   (Spain)

Author keywords

Papillomavirus; Prevalence; Sexually transmitted disease; Viral genotypes

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; CYTOLOGY; FEMALE; GENE AMPLIFICATION; GENOTYPE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PREVALENCE; SCREENING; SPAIN; UTERINE CERVICITIS; VIRUS INFECTION; WART VIRUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CERVIX UTERI; FEMALE; GENOTYPE; HUMANS; LONGITUDINAL STUDIES; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; SPAIN; VAGINAL SMEARS; YOUNG ADULT;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; PAPILLOMAVIRIDAE;

EID: 77949397708     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21697     Document Type: Article

References (36)

1. Bosch FX, Lorinz A, Muñoz N, Meijer CJ, Shah KV. 2002. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55:244-265.
2. Castle PE, Schiffman M, Herrero R, Hildesheim A, Rodriguez AC, Bratti MC, Sherman ME, Wacholder S, Tarone R, Burk RD. 2005. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 191:1808-1816.
3. Clifford G, Rana R, Franceschi S, Smith J, Gopugh G, Pimenta J. 2005a. Human papillomavirus genotype distribution in low-grade cervical lesion: Comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 14:1157-1164.
4. Clifford GM, Gallus S, Herrero R, Muñoz N, Sinjders PJ, Vaccarella S, Anh PT, Ferreccio C, Hewu NT, Matos E, Molan M, Rajkumar R, Ronco G, Sanjosé S, Shin HR, Sukvirach S, Thomas JO, Tunsakul S, Meijer CJ, Franceschi S, LARC HPV Prevalence Surveys Study Group. 2005b. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Angency for Research on Cancer HPV prevalence surveys: A pooled analysis. Lancet 366:991-998.
5. De Sanjosé S, Almirall R, Lloveras B, Front R, Díaz M, Muñoz N. 2003. Cervical human papillomavirus infection in female population in Barcelona, Spain. Sex Transm Dis 30:788-793.
6. De Sanjosé S, Díaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, Bosch FX. 2007. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: A meta-analysis. Lancet 7:453-459.
7. De Sanjosé S, Cortes X, Méndez C, Puig-Tintore L, Torne A, Roura E, Bosch FX, Castellsague X. 2008. Age at sexual initiation and number of sexual partners in the female Spanish population: Results from the AFRODITA survey. Eur J Obstet Gynecol Reprod Biol 140:234-240.
8. De Villiers EM, Fauquet C, Broker TR, Bernard HU, Zur Hausen H. 2004. Classification of papillomaviruses. Virology 324:17-27.
9. Dilner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, de Sanjosé S, Naucler P, Lloveras B,Kjaer S, Cuzick J, van Ballgooijen M, Clavel C, Iftner T. 2008. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: Joint European Cohort Study. Br Med J 337:969-972.
10. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, Markowitz LE. 2007. Prevalence of HPV infection among females in the United States. J Am Med Assoc 297:813-819.
11. Ferlay J, Bray F, Pisan P, Parkin DM. 2004.GLOBOCAN2002: Cancer incidence, mortality and prevalence worldwide. IARC CancerBase, 2.0 edition. Lyon: IARC Press.
12. Franceschi S. 2002. Human papillomavirus: A vaccine against cervical carcinoma uterine. Epidemiol Prev 26:140-144.
13. Frazer I. 2002. Vaccines for papillomavirus infection. Virus Res 89: 271-274.
14. FUTURE II Study Group. 2007. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356:1915-1927.
15. González C, Ortíz M, Canals J,Muñoz L, Jarrín I, de la Hera M, García-Sainz A, del Amo J. 2006. Higher prevalence of human papillomavirus in migrant women from Latin America in Spain. Sex Transm Infect 82:260-262.
16. Goodman M, Shvetson Y, McDuffie K, Wilkens LR, Zhu X, Thompson PJ, Ning L, Killeen J, Kamemoto L, Hernandez BY. 2003. Prevalence, acquisition, and clearance of cervical human papillomavirus infection among women with normal cytology: Hawaii Human Papillomavirus Cohort Study. Cancer Res 68:8813-8824.
17. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G, GlaxoSmithKline HPV Vaccine Study Group. 2004. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial. Lancet 364:1731-1732.
18. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LAM, Jansen KU. 2002. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347:1645-1651.
19. Kovacs K, Varnai AD, Bollmann M, Bankfalvi A, Szendy M, Speich N, Schmitt C, Pavor L, Bollmann R. 2008. Prevalence and genotype distribution of multiple human papillomavirus infection in the uterine cervix: A 7.5-year longitudinal study in a routine cytology-based screening population in West Germany. J Med Virol 80: 1814-1823.
20. Krambeck WM, Cadidé RM, Dalmarco EM, de Cordova CM. 2008. HPV detection and genotyping as an earlier approach in cervical cancer screening of the female genital tract. Clin Exp Obstet Gynecol 35:175-178.
21. Lytwyn A, Sellors JW, Mahony JB, Daya D, Chapman W, Ellis N, Roth P, Lorincz AT, Gafni A. 2000. Comparison of human papillomavirus DNA testing and repeat Papanicolaou test in women with low-grade cervical cytologic abnormalities: A randomized trial. HPV effectiveness in lowgrade Paps (HELP) Study No. 1 Group. Can Med Assoc J 163:701-707.
22. Manos MMTY, Wright DK. 1989. The use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. Cancer Cells 7:209-214.
23. Méndez F, Muñoz N, Posso H, Molano M, Moreno V, van den Brule AJ, Ronderos M, Meijer C, Munoz A, Instituto Nacional de Cancerologia Human Papillomavirus Study Group. 2005. Cervical coinfection with human papillomavirus (HPV) types and possible implications for the prevention of cervical cancer by HPV vaccines. J Infect Dis 192:1158-1165.
24. Muñoz N, Kato I, Bosch FX, Eluf-Neto J, De Sanjosé S, Ascunce N, Gili M, Izarzugaza I, Viladio P,Toreno MJ, Moero P, González LC, Tafur L, Walbooners JM, Shah KV. 1996. Risk factor for HPV DNA detection in middle-aged women. Sex Transm Dis 23:504-510.
25. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsague X, Shah KV, Snijders PJ,Meijer CJ. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer.NEngl J Med 348:518-527.
26. Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Radberg T, Strander B, Forslund O, Hansson BG, Rylander E, Dillner J. 2007. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 357:1650-1653.
27. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, de Carvalho NS, Skinner SR, Harper DM, Hedrick JA, Jaisamrarn U, Limson GA, Dionne M, Quint W, Spiessens B, Peeters P, Struyf F, Wieting SL, Lehtinen MO, Dubin G, HPV PATRICIA Study Group. 2007. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369:2161-2170.
28. Perrons C, Jelley R, Kleter B, Quint W, Brink N. 2005. Detection of persistent high risk human papillomavirus infections with Irbid capture II and SPF10/LiPA. J Clin Virol 32:278-285.
29. Santely M, Villa LL. 2008. Monitoring HPV vaccination. Vaccine 26: A24-A27.
30. Ting Y, Manos MM. 1990. Detection and typing of genital human papillomaviruses. In: Innis M, Gelfand D, Sninsky J, White T, editors. PCR protocols: A guide to methods and applications. San Diego, CA: Academic Press, Inc. pp 356-367.
31. Van der Graaf Y, Molijn A, Doornewaard H, Quint W, Van Door LJ, Van den Tweel J. 2002.Human papillomavirus and the long-term risk of cervical neoplasia. Am J Epidemiol 156:158-164.
32. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo RJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E. 2006. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6:256-257.
33. Walboomers JM, Jacobs MV, Manos MM,Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12-19.
34. Woodman CB, Collins S,Winter H, Bailey A, Ellis J, Prior P, Yates M, Rollason TP, Young LS. 2001. Natural history of cervical human papillomavirus infection in young women: A longitudinal cohort study. Lancet 357:1831-1836.
35. Wu EQ, Zhang GN, Yu XH, Ren Y, Fan Y, Wu YG, Kong W, Zha X. 2008. Evaluation of high-risk human papillomaviruses type distribution in cervical cancer in Sicuani province of China. BMC Cancer 8:101.
36. Zur Hausen H. 2002. Papillomaviruses and cancer: From basic studies to clinical application. Nat Rev Cancer 2:342-350.